Bruno Tillier
Bruno has been in charge of Synthelis since the very beginning, while it still was a Business Unit at Floralis, the technology transfer subsidiary at the University Joseph Fourier. When the company was independently launched in 2011, he became its CEO.
Before, Bruno worked for five years as account manager at Floralis, and also at Cisbio Bioassays in the immunoassay department.
Bruno has an M.Sc. in Medical Sciences from the South Alberta Cancer Research Institute (SACRI), Calgary, Canada. He also holds a Masters in Management from Reims Management School (RMS) and AgroParisTech (Masternova), where he focused on innovation in the Life Sciences.
In protein manufacturing, membrane proteins are well known to be challenging to produce in a functional form. SYNTHELIS’ patented cell-free technology allows customized expression and characterization of active proteins integrated in proteoliposomes. Membrane proteins are embedded directly into liposomes during the cell-free synthesis process allowing the proper folding of the protein. Following protein production, SYNTHELIS conducts quality controls to validate the target protein in terms of activity and structure.
Read More
Topics:
Cell-free technology,
Proteins
